To speed diagnoses and provide free genetic testing for young children in the United States and Canada who have unexplained…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
Cannabis-derived Epidiolex Cleared for Clinical Trials in Japan for Dravet, Lennox-Gastaut Syndromes
In a departure from general government policy, Japan has approved the cannabis compound Epidiolex for clinical trials in epileptic patients…
The National Institute of Neurological Disorders and Stroke (NINDS) has awarded NeuroCycle Therapeutics a $500,000 grant to test…
Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about…
With the goal of advancing development of new treatments for patients living with poorly controlled seizures, the Epilepsy Foundation…